Save Product
Product Details
Source
The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly produced from human 293 cells (HEK293). This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.
Antibody Type
Recombinant Monoclonal
Clone
AM359b
Isotype
Human IgG1, Kappa
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 has not been tested.
Application
ApplicationRecommended UsageELISA1:600-1:6000Purification
Protein A purified / Protein G purified.
Aggregation
Less than 10%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Detection of Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (MALS verified) titer by compitive-ELISA Assay. Serial dilutions of Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat. No. SPD-M265) were added into Human ACE2 / ACEH Protein, Fc Tag (Cat. No. AC2-H5257): HRP-SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1578 μg/mL (QC tested).
Protocol
Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat.No. SPD-M265) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Protocol
Immobilized Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (AM359b) (Cat. No. SPD-M265) at 2 μg/mL, add increasing concentrations of SARS-CoV-2 Spike RBD, His Tag (BA.2/Omicron) (Cat. No. SPD-C522g) and SARS-CoV-2 Spike Trimer, His Tag (BA.4/Omicron) (Cat. No. SPN-C5229) and SARS-CoV-2 Spike Trimer, His Tag (BA.5/Omicron) (Cat. No. SPN-C522e), and then add Biotinylated Anti-SARS-CoV-2 Spike RBD Antibody, Human IgG1 (AM130) (Cat. No. S1N-M13L3) at 0.5 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 19.53 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
A***n2022-10-04
LikesWe had purchased this antibody to be used in our in vitro pseudovirus neutralization assay. We had used it as a positive control for our assay. the assay worked very well and the antibody showed a dose dependent inhibition of the pseudovirus
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
